WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Jan. 21, 2008--Merck
Sharp & Dohme (MSD) today announced that the European Commission has
approved 'Januvia' (sitagliptin) for two additional uses for patients
with type 2 diabetes. This now makes sitagliptin the only dipeptidyl
peptidase-4 inhibitor (DPP-4 inhibitor) approved as an add-on therapy
to a sulphonylurea ('dual therapy'), or a sulphonylurea plus metformin
('triple therapy'), in the European Union (EU). It remains the only
DPP-4 inhibitor indicated for once-daily use.
